A proposal is the latest Obama administration effort to shift medical providers away from a fee-for-service model. » Read More
Valeant announces that CEO Mike Pearson is leaving and that former CFO Howard Schiller refused to quit the board to make room for Bill Ackman.
Bill Smead says now is the time to buy battered health care, amid "fantastic" dividends, and free cash flow.
Chinese authorities are hunting 300 people suspected of illegally selling spoiled vaccines to medical centers across the country, state media said.
Intrexon CEO tells CNBC's Power Lunch that he would not go to Brazil with Zika virus outbreak.
Most people will just need to check a box on their tax forms indicating if they had health coverage.
Two nutrition experts tell CNBC why Americans have such a tough time keeping the pounds off, and how that can change.
Emergency visits to the dentist skyrocket right after St. Patrick's Day because so many people get their teeth knocked out.
GlaxoSmithKline said its CEO Andrew Witty would retire in 12 months, prompting Britain's biggest drugmaker to start a formal search for his successor.
McKesson is cutting 1,600 jobs, or about 4 percent of its workforce, to slash costs after the company lost some key customers, Bloomberg reported.
Creditors of Valeant Pharmaceuticals are beginning to demand new terms that could further pressure the drugmaker's business model, sources said.
The Obama administration is accused of illegally giving insurers reimbursement to cut Obamacare customer out-of-pocket costs.
Almost 20 percent of rural counties have seen increases in the rate of premature deaths in the past decade.
Estimates say Trump's proposal to repeal Obamacare and make other changes could cost nearly $500 billion and lead to 21 million more uninsured people.
For the first time ever, the NFL has acknowledged that there is a link between football and brain damage.
Andrew Left of Citron Research explains why Mallinckrodt is worse than Valeant. Mark Trudeau, Mallinckrodt CEO, responds.
Presidential candidates may talk about combating high drug prices, but Express Scripts' Dr. Steve Miller says it takes more than talk to make it work.
Wall Street investor Bill Ackman says he is still confident in Valeant and he plans to be more proactive in his dealings with it.
Blackstone's president and a New School economist say it's time to take this looming retirement crisis seriously.
"This is a way to get rid of a terrible, terrible drug, oxycodone," CNBC's Jim Cramer says.
The pharmaceutical industry has donated more to Clinton's campaign than to any other candidate. This despite her harsh words for the industry.
Get the best of CNBC in your inbox